Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drink aims to help malnourished patients – but will they like it?

NCT ID NCT07452523

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new oral nutritional supplement called AYMES SWIFT in 40 adults who are malnourished or at risk of malnutrition. Participants will take the supplement for 7 days, and researchers will measure how well they tolerate it (digestive comfort) and how much they like it (taste, smell, texture). The goal is to see if this supplement is a good option for people who need extra nutrition due to illness.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AYMES SWIFT oral nutritional supplement (a food for special medical purposes)
What this could lead to
If successful, this could provide a well-tolerated and acceptable nutritional supplement for people with or at risk of disease-related malnutrition.
What could go wrong
This is a small, early-stage study focused on tolerance and acceptability, not on treating the underlying disease. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2022

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female •≥ 18 years of age * Identified as being malnourished/at risk of malnutrition-by-malnutrition screening tools \[i.e., MUST score ≥1, and/or using or requiring ONS at least once daily as part of nutritional management plan\] * Expected to receive at least one bottle of ONS per day * Written or electronic informed consent from patient, or verbally given consent countersigned by a witness for those physically unable to sign Exclusion Criteria: * Participants receiving parenteral nutrition or ≥70% total energy requirements from enteral tube feeding * Participants with major hepatic dysfunction (i.e., decompensated liver disease) * Participants with major renal dysfunction \[i.e., requiring filtration or stage 4/5 chronic kidney disease (CKD)\] * Participants with active/chronic gastrointestinal disease or impaired gastrointestinal function * Participants with significant dysphagia/high aspiration risk * Participation in other clinical intervention studies within 1 month of this study * Participants lacking mental capacity to consent * Allergy to any study product ingredients (appendix 2) * Investigator concern regarding ability or willingness of patient to comply with the study requirements.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Disease related malnutrition are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Preston Hill Surgery

    Harrow, HA3 9SN, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.